NEW YORK (GenomeWeb News) – Quidel said after the close of the market on Wednesday that revenues for the fourth quarter of 2013 are expected to total about $50 million.

The figure would represent a 7 percent drop from Q4 2012 revenues of $53.9 million, but it beats the consensus Wall Street estimate of $48.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.